中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

57 records (took 0.032 seconds)

    METHOD OF IDENTIFYING A GENE ASSOCIATED WITH A DISEASE OR PATHOLOGICAL CONDITION OF THE DISEASE
    12.
    发明申请
    METHOD OF IDENTIFYING A GENE ASSOCIATED WITH A DISEASE OR PATHOLOGICAL CONDITION OF THE DISEASE 审中-公开

    公开(公告)号：US20190017116A1

    公开(公告)日：2019-01-17

    申请号：US15647414

    申请日：2017-07-12

    Applicant: Macau University of Science and Technology

    Inventor： Liang Liu ,  Lai Han Leung ,  Ying Li ,  Xiao Jun Yao ,  Hu Dan Pan

    IPC: C12Q1/68 ,  G06F19/22 ,  G06F19/28 ,  G06F19/12

    Abstract: A method of identifying a gene associated with a disease or pathological condition of the disease includes: a) obtaining a first group of exome sequences from a first population suffering from the disease or pathological condition and a second group of exome sequences from a second population not having the disease or pathological condition; b) identifying one or more variants in the first group by comparing it with the second group, and optionally with a public database, to generate a first set of variant data; c) applying a variant quality score calibration tool with a truth sensitivity threshold to remove false-positive variants having a sensitivity lower than the threshold and background variants from the first set of variant data so as to obtain a second set of variant data; d) removing synonymous variants from the second set of variant data to obtain a third set of variant data; and e) identifying one or more deleterious variants from the third set of variant data using a gene burden analysis, optionally generating a fourth set of variant data.

    METHOD OF TREATING REFRACTORY RHEUMATOID ARTHRITIS
    13.
    发明申请
    METHOD OF TREATING REFRACTORY RHEUMATOID ARTHRITIS 审中-公开

    公开(公告)号：US20190008872A1

    公开(公告)日：2019-01-10

    申请号：US15644945

    申请日：2017-07-10

    Applicant: Macau University of Science and Technology

    Inventor： Liang Liu ,  Kam Wai Wong ,  Yuen Kwan Law ,  Cong Ling Qiu

    IPC: A61K31/56 ,  A61K31/519 ,  A61K31/573 ,  A61K31/165

    Abstract: A method for treating a subject suffering from refractory rheumatoid arthritis includes the step of administering an effective amount of a quinonemethide triterpenoid or a pharmaceutically tolerable salt, solvate or anhydrate thereof to the subject. Also is a method for inducing autophagy in a synovial fibroblast, and a method of inducing calcium mobilization in a synovial fibroblast. Further a pharmaceutical composition includes an effective dose of a quinonemethide triterpenoid and an anti-arthritis compound. The quinonemethide triterpenoid is suitable to treat refractory rheumatoid arthritis (RA) in particular ABC-protein-dependent RA and apoptosis-deficient RA. The quinonemethide triterpenoid also possesses significant inhibitory effects on the growth of synovial fibroblasts, in particular modulating the calcium homeostasis in multidrug-resistant rheumatoid arthritis synovial fibroblasts.

    ALK KINASE INHIBITOR AND ITS USE
    15.
    发明申请
    ALK KINASE INHIBITOR AND ITS USE 审中-公开

    公开(公告)号：US20180050037A1

    公开(公告)日：2018-02-22

    申请号：US15239288

    申请日：2016-08-17

    Applicant: Macau University of Science and Technology

    Inventor： Xiao-Jun Yao ,  Elaine Lai-Han Leung ,  Lian-Xiang Luo ,  Liang Liu

    IPC: A61K31/519

    CPC classification number: A61K31/519

    Abstract: A compound for treating a disease, in particular cancer like non-small cell lung cancer, exceptionally inhibits activity of oncogenic ALK kinase. Compositions, particularly pharmaceutical compositions, are provided comprising this compound. Methods for targeting cancer cells harboring an abnormality in the ALK gene are also The compound for treating a disease has certain structural elements, namely a tricyclic, more specifically heterocyclic, backbone as the core part of the compound at least one highly electronegative atom in form of a tertiary amine attached to the backbone via an at most 6-membered linking group with a terminal highly electronegative atom in form of a nitrogen as secondary amine, and a further hydrophobic moiety fused to the backbone. The structural components allow for an advantageous interaction with the ALK kinase domain. The compound therefor represents a highly promising treatment option for patients in particular those bearing ALK-dependent non-small cell lung cancer.

Patent Agency Ranking